Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Donor-specific antibodies require preactivated immune system to harm renal transplant

C. Süsal, B. Döhler, A. Ruhenstroth, C. Morath, A. Slavcev, T. Fehr, E. Wagner, B. Krüger, M. Rees, S. Balen, S. Živčić-Ćosić, DJ. Norman, D. Kuypers, MP. Emonds, P. Pisarski, C. Bösmüller, R. Weimer, J. Mytilineos, S. Scherer, TH. Tran, P....

. 2016 ; 9 (-) : 366-71. [pub] 20160605

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013751

BACKGROUND: It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. METHODS: The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. FINDINGS: A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83.1±3.9% and 84.3±2.8%, P=0.81). A strikingly lower 3-year graft survival rate of 62.1±6.4% was observed in patients who were both sCD30 and DSA positive (HR 2.92, P<0.001). Even in the presence of strong DSA with ≥5000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. INTERPRETATION: Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013751
003      
CZ-PrNML
005      
20230207113116.0
007      
ta
008      
170413s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2016.06.006 $2 doi
035    __
$a (PubMed)27333031
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Süsal, Caner $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany. Electronic address: caner.suesal@med.uni-heidelberg.de.
245    10
$a Donor-specific antibodies require preactivated immune system to harm renal transplant / $c C. Süsal, B. Döhler, A. Ruhenstroth, C. Morath, A. Slavcev, T. Fehr, E. Wagner, B. Krüger, M. Rees, S. Balen, S. Živčić-Ćosić, DJ. Norman, D. Kuypers, MP. Emonds, P. Pisarski, C. Bösmüller, R. Weimer, J. Mytilineos, S. Scherer, TH. Tran, P. Gombos, P. Schemmer, M. Zeier, G. Opelz, . ,
520    9_
$a BACKGROUND: It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. METHODS: The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. FINDINGS: A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83.1±3.9% and 84.3±2.8%, P=0.81). A strikingly lower 3-year graft survival rate of 62.1±6.4% was observed in patients who were both sCD30 and DSA positive (HR 2.92, P<0.001). Even in the presence of strong DSA with ≥5000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. INTERPRETATION: Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antigen Ki-1 $x krev $7 D017730
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a přežívání štěpu $7 D006085
650    _2
$a HLA antigeny $x krev $x imunologie $7 D006680
650    _2
$a lidé $7 D006801
650    _2
$a imunitní systém $x metabolismus $7 D007107
650    _2
$a chronické selhání ledvin $x terapie $7 D007676
650    12
$a transplantace ledvin $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a T-lymfocyty $x cytologie $x metabolismus $7 D013601
650    _2
$a dárci tkání $7 D014019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Döhler, Bernd $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a Ruhenstroth, Andrea $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a Morath, Christian $u Division of Nephrology, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Slavcev, Antonij $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
700    1_
$a Fehr, Thomas $u Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Wagner, Eric $u Immunology and Histocompatibility Laboratory, CHU de Québec-Université Laval, Québec, QC, Canada; Department of Microbiology, Infectious Diseases and Immunology, Université Laval, Québec, QC, Canada.
700    1_
$a Krüger, Bernd $u University Medical Centre Mannheim, Mannheim, Germany.
700    1_
$a Rees, Margaret $u Welsh Transplantation and Immunogenetics Laboratory, Cardiff, United Kingdom.
700    1_
$a Balen, Sanja $u Departments of Transfusion Medicine and Nephrology, Dialysis, Kidney Transplantation, University Hospital Centre, Rijeka, Croatia.
700    1_
$a Živčić-Ćosić, Stela $u Departments of Transfusion Medicine and Nephrology, Dialysis, Kidney Transplantation, University Hospital Centre, Rijeka, Croatia.
700    1_
$a Norman, Douglas J $u Oregon Health and Science University, Portland, OR, USA.
700    1_
$a Kuypers, Dirk $u Department of Nephrology and Renal Transplantation, Leuven, Belgium.
700    1_
$a Emonds, Marie-Paule $u Blood Transfusion Center, University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Pisarski, Przemyslaw $u Transplantation Surgery, University of Freiburg, Freiburg, Germany.
700    1_
$a Bösmüller, Claudia $u Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria.
700    1_
$a Weimer, Rolf $u Department of Internal Medicine, University Clinic of Giessen and Marburg, Giessen, Germany.
700    1_
$a Mytilineos, Joannis $u Department of Transplantation Immunology, Institute of Transfusion Medicine, University Clinic Ulm, Ulm, Germany.
700    1_
$a Scherer, Sabine $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a Tran, Thuong H $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a Gombos, Petra $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a Schemmer, Peter $u Transplantation and General Surgery, University of Heidelberg, Heidelberg, Germany.
700    1_
$a Zeier, Martin $u Division of Nephrology, University of Heidelberg, Heidelberg, Germany. $7 xx0281649
700    1_
$a Opelz, Gerhard $u Transplantation Immunology, Institute of Immunology, Heidelberg, Germany.
700    1_
$a ,
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 9, č. - (2016), s. 366-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27333031 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20230207113112 $b ABA008
999    __
$a ok $b bmc $g 1200216 $s 974529
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 9 $c - $d 366-71 $e 20160605 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace